Literature DB >> 26066289

Diagnostic performance of IOTA simple rules for adnexal masses classification: a comparison between two centers with different ovarian cancer prevalence.

Beatriz Ruiz de Gauna1, David Rodriguez1, Begoña Olartecoechea2, María Aubá2, Matías Jurado2, María Dolores Gómez Roig1, Juan Luis Alcázar3.   

Abstract

OBJECTIVE: The aim of this study was to compare the diagnostic performance of the IOTA simple rules for classifying adnexal masses when used in two centers with different ovarian cancer prevalence. STUDY
DESIGN: A prospective study was performed between June 2012 and December 2013 at two different centers with different ovarian cancer prevalence. Center A had high ovarian malignancy prevalence and Center B had low malignancy rates. Eligible patients were all women diagnosed as having a persistent adnexal mass. Examiners had to analyze the masses according to IOTA simple rules (SR) providing a diagnosis of malignant, benign or inconclusive. Those cases classified as inconclusive were then examined by an expert examiner (the same examiner in center A, a different examiner in center B), who had to classify the mass as malignant, benign or uncertain according to his subjective impression (SI). Definitive histologic diagnosis from tumors removed surgically was used as gold standard. The diagnostic performance was assessed by calculating the sensitivity and specificity, positive and negative likelihood ratios, for SR and SR+SI assessments. McNemar test was used for comparing sensitivity and specificity.
RESULTS: During this period, 247 women were eligible for this study. The rate of inconclusive masses was 18.4% and 18.0% for centers A and B, respectively (p>0.05). Ovarian malignancy rate was significantly higher in center A as compared with center B (27.2% versus 11.3%), (p=0.001). When analyzing only cases classifiable by SR, sensitivity in center A was significantly higher (100% versus 84.6% p=0.001), but specificity was similar in both centers (93.9% and 95.8% respectively). When analyzing SR plus SI, sensitivity in center A was significantly higher (100% versus 86.7% p=0.001), but specificity was similar in both centers (89.9% and 88.8%, respectively).
CONCLUSIONS: The diagnostic performance in terms of sensitivity of IOTA rules is higher in a center with higher prevalence of ovarian malignancy.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adnexal mass; Ovarian cancer; Ultrasound

Mesh:

Year:  2015        PMID: 26066289     DOI: 10.1016/j.ejogrb.2015.05.024

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  4 in total

1.  Validation of the Performance of International Ovarian Tumor Analysis (IOTA) Methods in the Diagnosis of Early Stage Ovarian Cancer in a Non-Screening Population.

Authors:  Wouter Froyman; Laure Wynants; Chiara Landolfo; Tom Bourne; Lil Valentin; Antonia Testa; Povilas Sladkevicius; Dorella Franchi; Daniela Fischerova; Luca Savelli; Ben Van Calster; Dirk Timmerman
Journal:  Diagnostics (Basel)       Date:  2017-06-02

2.  Predicting Malignancy in Adnexal Masses by the International Ovarian Tumor Analysis-Simple Rules.

Authors:  Vrushti Solanki; Pratibha Singh; Charu Sharma; Navdeep Ghuman; Binit Sureka; Shashank Shekhar; Meenakshi Gothwal; Garima Yadav
Journal:  J Midlife Health       Date:  2021-01-21

3.  Diagnostic Performance of Risk of Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI) and Expert Ultrasound Assessment in a Pelvic Mass Classified as Inconclusive by International Ovarian Tumour Analysis (IOTA) Simple Rules.

Authors:  Siew Fei Ngu; Yu Ka Chai; Ka Man Choi; Tsin Wah Leung; Justin Li; Gladys S T Kwok; Mandy M Y Chu; Ka Yu Tse; Vincent Y T Cheung; Hextan Y S Ngan; Karen K L Chan
Journal:  Cancers (Basel)       Date:  2022-02-05       Impact factor: 6.639

Review 4.  ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.

Authors:  Dirk Timmerman; François Planchamp; Tom Bourne; Chiara Landolfo; Andreas du Bois; Luis Chiva; David Cibula; Nicole Concin; Daniela Fischerova; Wouter Froyman; Guillermo Gallardo Madueño; Birthe Lemley; Annika Loft; Liliana Mereu; Philippe Morice; Denis Querleu; Antonia Carla Testa; Ignace Vergote; Vincent Vandecaveye; Giovanni Scambia; Christina Fotopoulou
Journal:  Int J Gynecol Cancer       Date:  2021-06-10       Impact factor: 3.437

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.